Aligos Therapeutics(US:ALGS)2025-11-06 13:30Financial Performance - Aligos Therapeutics reported a net loss of $31.5 million for Q3 2025, with a basic and diluted net loss per share of $(3.04), compared to a net loss of $19.3 million or $(3.07) per share in Q3 2024[7]. - Revenue from customers for Q3 2025 was $741,000, down from $1.25 million in Q3 2024, while total revenue for the nine months ended September 30, 2025, was $2.02 million compared to $3.01 million for the same period in 2024[15]. Research and Development - Research and development (R&D) expenses increased to $23.9 million in Q3 2025 from $16.8 million in Q3 2024, primarily due to higher third-party expenses for the pevifoscorvir sodium Phase 2a clinical trial[8]. - Total operating expenses for Q3 2025 were $29.1 million, compared to $21.4 million in Q3 2024, reflecting increased R&D and general administrative costs[15]. - The Phase 2 B-SUPREME study of pevifoscorvir sodium is ongoing, with interim data expected in 1H and 2H 2026, and topline data anticipated in 2027[6]. - The company has completed 96 weeks of dosing in the Phase 1 study of pevifoscorvir sodium, with data readouts expected at The Liver Meeting® 2025[6]. Cash and Funding - Cash, cash equivalents, and investments totaled $99.1 million as of September 30, 2025, up from $56.9 million as of December 31, 2024, expected to fund operations into Q3 2026[5]. - Aligos is exploring various funding options for continued development, including potential out-licensing of ALG-055009[6]. General and Administrative Expenses - General and administrative (G&A) expenses rose to $5.2 million in Q3 2025 from $4.6 million in Q3 2024, mainly due to higher legal and related expenses[9]. Development Pipeline - Aligos maintains enthusiasm for its development pipeline, including ALG-055009, which is in discussions with potential partners for obesity and MASH[2].